In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shawn Singh, Chief Executive Officer and Director at Vistagen Therapeutics.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Shawn, covering:
What life is like running a public company and how that is impacted depending upon the season of the capital markets
The ups, downs and pivots of a biopharmaceutical company that’s led it down a mission of transforming the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders
How the pandemic has magnified mental health issues and their prevalence among young people, and why finding a radically social transformative treatment is needed
Why collaboration is key when developing several drug candidates and how partnerships can happen at any stage of the lifecycle
His views on CROs, CDMOs, what is essential to outsource in the vendor universe… and the most critical asset to a biotech boss
Shawn is an experienced public company Chief Executive Officer and Director. He has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles.